VR Logo

Ventyx Biosciences Inc. (VTYX) download report


Healthcare | Biotechnology & Pharma Research

Ventyx Biosciences Inc. (VTYX) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders.

IPO Date: 21-Oct-2021

Exec. Chair: Dr. Sheila K. Gujrathi M.D.

Founder, CEO & Director: Dr. Raju S. Mohan Ph.D.

Listing: NASDAQ: VTYX

Country: United States

Headquarters: Encinitas, CA

Website: https://www.ventyxbio.com

Key Facts

Market cap: $679.36 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-80.65 Mln

Cash: $254.35 Mln

Total Debt: $1.32 Mln

Insider's Holding: 4.94%

Liquidity: Low

52 Week range: $9.50 - 26.00

Shares outstanding: 50,850,300

Stock Performance

Time Period Ventyx Biosciences (VTYX) S&P BSE Sensex S&P Small-Cap 600
YTD-41.29-8.97-19.67
1 month-37.81-3.38-9.84
3 months-2.35-7.93-15.05
1 Year--0.55-18.10
3 Years--10.415.71
5 Years--11.455.53
10 Years--12.0510.04
As on 29-Jun-2022